HER2 Gastrointestinal Tract

TAT: 24-48 Hours
Methodology: IHC
Disease Group: Gastrointestinal Tract

Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet. 2010 Oct 16; 376(9742):687-697. Erratum: 2010 Oct 16;376(9749):1302. PubMed 20728210